Automate Your Wheel Strategy on FOLD
With Tiblio's Option Bot, you can configure your own wheel strategy including FOLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FOLD
- Rev/Share 1.8546
- Book/Share 0.6634
- PB 12.3005
- Debt/Equity 2.1699
- CurrentRatio 3.2092
- ROIC 0.0521
- MktCap 2515233292.0
- FreeCF/Share -0.1588
- PFCF -51.4215
- PE -65.9663
- Debt/Assets 0.5437
- DivYield 0
- ROE -0.1977
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | FOLD | Needham | Hold | Buy | -- | $14 | Sept. 18, 2025 |
| Upgrade | FOLD | Morgan Stanley | Equal Weight | Overweight | -- | $108 | July 17, 2025 |
| Downgrade | FOLD | Morgan Stanley | Overweight | Equal Weight | $17 | $12 | Dec. 13, 2024 |
| Initiation | FOLD | Jefferies | -- | Buy | -- | $18 | Sept. 6, 2024 |
News
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Read More
3 Of My Favorite Biotech Stocks Under $10
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
Read More
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Read More
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda®
Read More
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
Read More
The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Read More
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Read More
Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley L. Campbell - CEO, President & Director Jeffrey P.
Read More
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m.
Read More
U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association
Read More
The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Physician group filed an amicus brief in Chiles v. Salazar defending the right of licensed therapists to offer "conversion therapy" in gender dysphoria.
Read More
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma
Published: June 12, 2025 by: Seeking Alpha
Sentiment: Positive
Amicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease and is driving consistent revenue growth. Key growth drivers for Galafold include expanding patient reach, new markets, increased market share, and high patient adherence.
Read More
New Strong Sell Stocks for June 3rd
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Negative
FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.
Read More
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured.
Read More
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Read More
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Read More
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Read More
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Read More
NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.
Read More
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
Read More
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Read More
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus' common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks.
Read More
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua …
Read More
About Amicus Therapeutics, Inc. (FOLD)
- IPO Date 2007-05-31
- Website https://amicusrx.com
- Industry Biotechnology
- CEO Bradley L. Campbell
- Employees 499